Group 1 - The company emphasizes its commitment to research and innovation, establishing three major research and production bases: Zhifei Green Bamboo, Zhifei Longke Ma, and Chongqing Chengan, along with an innovation incubation center in Beijing, to achieve a synergistic development of "prevention & treatment" [1] - Currently, several products are in the上市审评阶段, including the human diploid rabies vaccine, quadrivalent meningococcal conjugate vaccine, 15-valent pneumococcal conjugate vaccine, and liraglutide injection [1]

Group 1 - The core announcement is that Boya Bio has received approval from the National Medical Products Administration for three specifications of intravenous human immunoglobulin (pH4) [1] - The approval was granted to Green Cross (China) Biological Products Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings Limited, which is itself a wholly-owned subsidiary of Boya Bio [1] - The approval notification includes three specific notification numbers: 2026B00463, 2026B00465, and 2026B00466 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 本公告由榮昌生物製藥（煙台）股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.09(2)(a)條及第13.10B條項下披露責任以及證券及期貨條 例（香港法例第571章）第XIVA部項下的內幕消息條文作出。 本公司於本公告載列2025年度（「本期」）財務數據，數據乃根據《中國企業會計準 則》編製，且僅為初步會計數據，未經會計所審計。本公告所載數據與本公司年 報所披露的最終數據或有區別。投資者在買賣本公司股份時務請審慎行事。 一、本期業績預告情況 （一）業績預告期間 2025年1月1日至2025年12月31日。 1 （二）業績預告情況 (1) 經本公司財務部門初步測算，預計2025 年度營業收入約人民幣 325,000萬元，與 ...

Core Viewpoint - The company, Baili Tianheng, anticipates a significant decline in net profit for 2025, projecting a loss of approximately 1.1 billion yuan, which represents a year-on-year decrease of about 129.67% [1] Financial Performance - The projected net profit for 2025 is around -1.1 billion yuan, indicating a substantial loss compared to the previous year [1] - The decrease in revenue is primarily attributed to the recognition of a larger intellectual property income from a previous upfront payment of 800 million USD from BMS in the prior year, compared to the milestone payment of 250 million USD received during the current reporting period [1] Research and Development - The company is increasing its R&D investment significantly to accelerate the development of its product pipeline and maintain its competitive edge [1] - The collaboration with Bristol-Myers Squibb (BMS) on the drug iza-bren is progressing well, with the achievement of a milestone in the global II/III phase key registration clinical trial, leading to the receipt of a milestone payment [1]

Core Viewpoint - Changchun Gaoxin (000661) expects a significant decline in net profit for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The increase in research and development expenses is attributed to the advancement of product development in traditional and innovative areas [1] Group 2: Product Development and Sales - The company has launched several new products, including the first domestic innovative biological agent for acute gouty arthritis, Jinbeixin (Fuxin Qibai Dantong) [1] - Efforts are ongoing to promote key products such as Jinbeixin and Meishiya, with a focus on enhancing sales promotion, terminal coverage, and channel penetration [1] Group 3: Market Adaptation and Policy Response - The company successfully included long-acting growth hormone products in the national medical insurance catalog, adapting sales policies and pricing in response to industry policy changes [2] - Adjustments in product sales policies and pricing, along with the arrangement of product delivery schedules, have led to a reduction in related revenue and net profit [2]

Core Viewpoint - Junshi Biosciences (688180) forecasts a net profit attributable to shareholders of approximately -870 million yuan for 2025, indicating a significant reduction in losses compared to the previous year, with a decrease of about 408 million yuan or 31.85% year-on-year [1] Group 1 - The company expects to report a net loss for 2025, but the loss amount is significantly narrowed compared to the same period last year [1] - The improvement in financial performance is attributed to the implementation of the "quality improvement and efficiency enhancement" action plan, which has notably enhanced commercial capabilities while strengthening cost control and resource focus [1] - During the reporting period, the company maintained efficient progress on its core pipeline while controlling expenses, advancing several innovative drugs with international market competitiveness, including JS207, JS212, and JS213 [1]

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately CNY 2.5 billion in revenue for the fiscal year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately CNY 1.353 billion, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around CNY 873 million, which is a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about CNY 799 million, a decrease of approximately 37.62% year-on-year [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be around CNY 985 million, down by about 23.64% year-on-year [1] - After excluding the impact of share-based payments and non-recurring gains and losses, the net loss is projected to be approximately CNY 911 million, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi), which saw significant sales growth in the domestic market [1] - As of the date of this announcement, Tuoyi has been approved for 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody included in the national medical insurance catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, and others [2] Strategic Initiatives - Despite the expected net loss for 2025, the company has significantly narrowed its loss compared to the previous year, attributed to the implementation of the "quality improvement and efficiency enhancement" action plan [2] - The company has improved its commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing multiple innovative drugs with international market competitiveness, including JS207 (a PD-1/VEGF dual antibody), JS212 (an EGFR/HER3 ADC), and JS213 (a PD-1/IL-2 fusion protein), which are in various stages of clinical trials [2] - JS207 is currently in Phase II clinical research, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase [2]

Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately 2.5 billion yuan in revenue for the year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately 1.353 billion yuan, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around 873 million yuan, a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about 799 million yuan, a decrease of approximately 37.62% year-on-year [1] - The net loss after excluding non-recurring gains and losses is expected to be around 985 million yuan, down about 23.64% year-on-year [1] - The net loss after excluding both share-based payments and non-recurring items is projected to be approximately 911 million yuan, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®), which saw significant sales growth in the domestic market [1] - As of the announcement date, Tuoyi® has been approved for 12 indications in mainland China, all of which are included in the national medical insurance catalog, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the catalog [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, Kuwait, Pakistan, Canada, and Bahrain [2] Strategic Initiatives - Despite the expected net loss, the company has significantly narrowed its loss compared to the previous year, mainly due to the implementation of the "quality improvement and efficiency enhancement" action plan, which has improved commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing its core pipeline efficiently while controlling expenses, rapidly progressing clinical trials for several innovative drugs with international market competitiveness, including JS207 (PD-1/VEGF dual antibody), JS212 (EGFR/HER3 ADC), and JS213 (PD-1/IL-2 fusion protein) [2] - JS207 is currently in Phase II clinical trials, exploring combinations with chemotherapy, monoclonal antibodies, ADCs, and other drugs across multiple tumor types, with ongoing Phase II trials for the combination of JS207 and JS212 [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase as soon as possible [2]

Group 1 - The core viewpoint of the article highlights that the company's fourth-quarter revenue was low, which negatively impacted its quarterly profit due to the seasonal nature of its main products, antivenom and tetanus immunoglobulin [1] - The company noted that the incidence rates of snake bites and trauma are significantly higher in summer, leading to larger sales volumes in the second and third quarters, while the first and fourth quarters see lower sales [1] - The company is actively seeking quality acquisition targets to promote its external growth strategy, aligning with its development needs and external environmental conditions [1] Group 2 - The company emphasizes its commitment to adhering to information disclosure regulations and will fulfill its disclosure obligations if there are clear acquisition plans that meet the disclosure standards [1] - Relevant information regarding acquisitions will be based on the company's official announcements [1]

Core Viewpoint - Rongchang Biopharma (688331.SH) expects significant revenue growth and profitability turnaround in 2025, driven by strong sales of core products and strategic partnerships [1] Financial Performance - The company anticipates a revenue of approximately 3.25 billion yuan in 2025, an increase of about 1.53 billion yuan or 89% compared to the previous year [1] - Expected net profit attributable to shareholders is around 716 million yuan, marking a turnaround from losses in the previous year [1] - The net profit after deducting non-recurring gains and losses is projected to be approximately 78.5 million yuan, also indicating a return to profitability [1] Product and Market Development - Core products, Taitasip and Vidisicimab, have seen rapid growth in domestic sales, becoming the main drivers of revenue [1] - The company has successfully established a significant partnership with Vor Biopharma Inc, granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [1] Cost Management and Efficiency - The company has implemented management optimizations and production process iterations, resulting in reduced unit production costs and improved gross margins [1] - A notable decrease in sales expense ratio has contributed to enhanced profitability efficiency [1]